REVIEW Tranexamic acid competitively inhibits activation of plasminogen via binding to the kringle domain, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003;63(13):1417-33.
Arayne, M. Saeed; Journal of Molecular Structure 2008, V891(1-3), P475-480